PTEN loss is not associated with trastuzumab resistance in metastatic breast cancer

Kocar M., Bozkurtlar E., Telli F., Turhal N. S., Kaya H., Kocar H., ...Daha Fazla

JOURNAL OF BUON, cilt.19, ss.900-905, 2014 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19
  • Basım Tarihi: 2014
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.900-905
  • Anahtar Kelimeler: breast cancer, HER2, PI3K pathway, PTEN loss, trastuzumab, GENE PROTEIN PRODUCT, PI3K PATHWAY, EXPRESSION, THERAPY, PIK3CA, MUTATIONS
  • Marmara Üniversitesi Adresli: Evet

Özet

Purpose: Although the clinical benefits of trastuzumab are well known, intrinsic or acquired resistance is a commonly encountered clinical condition. A potential resistance mechanism is aberrant downstream signal transmission due to loss of phosphatase and tensine homologue (PTEN). This study investigated the relationship between trastuzumab response and loss of PTEN in metastatic breast cancer patients.